Answers are grounded in this paper and cite their sources.
Galangin is a natural flavonoid with reported anticancer effects, but how it acts in non-small cell lung cancer (NSCLC) is not fully understood. This study explored its potential targets and effects on NSCLC cells. We combined network pharmacology, molecular docking, 100-ns molecular dynamics simulations, and in vitro experiments. We identified 101 overlapping targets of galangin and NSCLC. Protein–protein interaction analysis highlighted six hub genes: AKT1 , STAT3 , MYC , HIF1A , CASP3 , and IL6 . Among the enriched pathways, PI3K/AKT signaling ranked highest. Molecular docking predicted favorable interactions between galangin and all six hub proteins, while molecular dynamics simulations suggested stability of the galangin–AKT1 complex. In vitro experiments showed that galangin reduced the proliferation, migration, and invasion of A549 and H1299 cells. It also decreased p-PI3K and p-AKT levels, with little change in total PI3K and AKT levels. 740Y-P partially reversed galangin-induced inhibition of migration and invasion and restored p-PI3K/p-AKT levels. Galangin inhibits the proliferation, migration, and invasion of NSCLC cells, at least in part by inhibiting PI3K/AKT signaling. This work provides a mechanistic basis for developing galangin as a potential therapeutic solution for NSCLC.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: